Acadia Pharmaceuticals Inc. (ACAD) — Analysis Summary
Acadia Pharmaceuticals Inc. (ACAD) has a market cap of $3.71B with year-over-year revenue growth of +11.9%. Net margin stands at 36.5%. The stock trades at a P/E ratio of 9.9.
Key Takeaways
- Revenue changed +11.9% year-over-year
- Net margin of 36.5%
- P/E ratio of 9.9
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ACAD posted revenue growth of +11.9% and trades at a P/E of 9.9.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.